Mammalian hematopoietic stem cell (HSC) commitment and differentiation into lymphoid lineage cells proceed through a series of developmentally restricted progenitor compartments. A complete understanding of this process, and how it differs from HSC commitment and differentiation into cells of the myeloid/erythroid lineages, requires the development of model systems that support HSC commitment to the lymphoid lineages. We now describe a human bone marrow stromal cell culture that preferentially supports commitment and differentiation of human HSC to CD19+ B-lineage cells. Fluorescence activated cell sorterpurified CD34++/lineage-cells were isolated from fetal bone marrow and cultured on human fetal bone marrow stromal cells in serum-free conditions containing no exogenous cyto- (10 ng/ml), or by the addition of goat anti-IL-7 neutralizing antibody. These results indicate a profound difference between mouse and human in the requirement for 1L-7 in normal B-cell development, and provide an experimental system to identify and characterize human bone marrow stromal cell-derived molecules crucial for human B lymphopoiesis.
molecules crucial for human B lymphopoiesis.
Hematopoietic stem cells (HSC) are defined by their longterm self-renewing capacity and their potential to differentiate into all the major lineages of blood-forming cells. CD34 is expressed on all human HSC and restricted hematopoietic progenitors (1) , and anti-CD34 monoclonal antibodies (mAbs) can be used to purify HSC for fundamental studies of blood cell development and clinical bone marrow/cord blood transplantation (1) . One of the unresolved questions in blood cell development is the mechanism by which HSC commit to the lymphoid lineages. Most lymphohematopoietic schemes portray the existence of a lymphoid stem cell-i.e., a cell with the capacity to become a T, B, or natural killer cell-but no other hematopoietic cell. Formal proof supporting the existence of a lymphoid stem cell is lacking (2) , but two recent reports provided insight into the nature of putative lymphoid stem cells. Georgopoulos et al. (3) reported that targeted disruption of the Ikaros gene results in a mouse lacking T, B, and natural killer cells, whereas the myeloid/erythroid compartments are essentially normal. Although this does not prove the existence of a common lymphoid stem cell, it does suggest that the Ikaros transcription factor may play a role in lymphoid cell fate. In a different approach using human bone marrow, Galy et al. (4) showed that a progenitor population with the phenotype CD34+/lineage-/CD45RA+/CD10+ could give rise to T, B, natural killer, and dendritic cells, but not myeloid/erythroid cells. This is the strongest evidence to date that normal human bone marrow contains a common lymphoid stem cell.
We know relatively little about the role of the bone marrow microenvironment in regulating human HSC commitment to the B lineage. Purified CD34+ human fetal bone marrow stem cells have been examined for their capacity to differentiate into the B lineage. Two studies found that plating CD34+/lineagehuman fetal bone marrow cells on a murine bone marrow stromal cell (BMSC) line yielded CD33+ and CD19+ B-lineage cells after 4-6 weeks of culture (5, 6) . Similarly, cord-blood enriched CD34+ stem cells plated on the S17 murine BMSC line gave rise to CD19+/surface Ig-B-cell precursors with the capacity to proliferate for >12 weeks (7) . Another study cultured CD34+/CD38+/HLA-DR-fetal bone marrow stem cells in medium containing interleukin (IL)-3, IL-6, stem cell factor (SCF), granulocyte/macrophage colony-stimulating factor, erythropoietin, basic fibroblast growth factor, and insulin-like growth factor 1 (8) . In the absence of a BMSC feeder layer the stem cells developed into multiple lymphohematopoietic lineages, including CD10+/CD19+ B-lineage cells (8) .
Our laboratory has developed a serum-free human BMSC culture that supports the IL-7-enhanced growth of CD19+/ CD34+ human pro-B cells (9, 10) . In the current study we (12) . Streptavidinphycoerythrin was used to detect biotinylated mAb in one-or two-color analysis. Streptavidin-QuantumRed (Sigma) was used to detect biotinylated mAb in three-color analysis. Quantitation of CD19+ cells by the flow cytometry-based microsphere assay was conducted as described (13) . The microsphere assay is sensitive to a detection level of 100 CD19+ cells/well.
Cytoplasmic ,u Staining. Acetone-fixed cytospins were stained with rhodamine-conjugated goat antibody to , or y H chains (Southern Biotechnology Associates) as described (12 
RESULTS
Isolation of HSC and Pro-B Cells. We have described a BMSC culture which supports the survival, growth, and differentiation of pro-B cells (10) . We sought to determine whether this BMSC-dependent/serum-free culture could support HSC commitment to the B lineage. We isolated CD34++ HSC depleted of lineage-committed progenitors, since CD34++ HSC contain the developmental capacity to differentiate into T, B, and myeloid cells (6) . Fig. 1 
BMSC Support the Differentiation of HSC to the B Lineage. The expression of CD10, CD19, CD34, and ,u H chain is shown in Fig. 3 . Following 10-day culture of HSC >95% of the analyzed cells were CD19+, and virtually all CD19+ cells were CD10+. Twenty-two percent of pro-B cells were present by day 10; this number decreased to 4% by day 19. Conversely, CD19+/surface ,u H chain+ immature B cells increased from 17% at day 10 to 27% at day 19. An increase in CD19 expression was observed between days 10 and 19 (Fig. 3) , consistent with an ongoing maturation of the total B-lineage population.
A time course experiment was conducted to evaluate the kinetics of HSC commitment and differentiation into the B lineage (Fig. 4) . Less than 0.25% of the HSC (or -10 cells/ well) plated at day 0 were CD19+. By day 4, the number of CD19+ cells had increased to -4400/well (Fig. 4A) and comprised -65% of the analyzed cells (Fig. 4B) . The CD19+ cell number expanded to -23,000 by day 19 (Fig. 4A ) and comprised 93% of the analyzed cells (Fig. 4B ). Cells expressing ,u H chain were detected on day 7 (0.5%), but L chain+ cells were not detected. By day 12, -6% and --3% of the CD19+ cells were H chain+ and L chain+, respectively (Fig. 4C) . By day 19, -35% and -28% of the CD19+ cells were H chain+ and L chain+, respectively (Fig. 4C ). In addition, 30-40% cytoplasmic ,u+ cells were present in three separate experi- population of 5 x 103 was limited without IL-7. When analyzed at day 10, 1.6 x 104 (range, 0.3 x 104 to 3.9 x 104, n = 9 experiments) CD19+ cells were present, and in all experiments CD19+ cells declined by day 19, at which time only 0.4 x 104 (range, 0.1 X 104 to 1.1 x 104, n = 9 experiments) CD19+ cells were present. These collective results are consistent with the experiment shown in Fig. 2. As expected (9, 10) , analysis of variance showed that the addition of exogenous IL-7 significantly enhanced the proliferation of pro-B cells (P = 0.015, n = 8 experiments on day 10, and P = 0.003, n = 7 experiments on day 19 ).
Because endogenous IL-7 production by BMSC could be partially responsible for the commitment and expansion of HSC to the B lineage, we quantitated IL-7 production by ELISA. Fetal BMSC produced -1-2 pg/ml of IL-7, and this concentration was not altered by coincubation of BMSC with HSC or pro-B cells for up to 20 days. This level of IL-7 does not support the growth of the IL-7-dependent murine pre-Bcell line 2E8 (data not shown). To evaluate the potential contribution of this low level of BMSC IL-7 production, we added a goat anti-human IL-7 neutralizing antibody to the HSC/fetal BMSC cultures. Anti-IL-7 had no effect on CD19+ cell numbers emerging after 19 days in culture, compared with medium containing normal goat IgG or medium alone (n = 4 experiments, data not shown). Antibody to IL-6 and SCF also had no effect on the number of CD19+ cells recovered from HSC/fetal BMSC cultures.
DISCUSSION
Human B-cell development occurs in multiple organ sites during embryonic life (i.e., bone marrow, liver, lung, kidney, and omentum), and only in the bone marrow from neonatal through adult life (14) (15) (16) (6) . In preliminary studies we have shown that CD19-/CD34+ (CD34 low density) fetal bone marrow cells fail to give rise to CD19+ B-lineage cells (unpublished observations), confirming the importance of initiating the cultures with CD34++ HSC to achieve B-cell development.
The two most salient attributes of this study are (i) the cellular components of the culture system are all of human fetal bone marrow origin, and (ii) the BMSC culture supports multiple stages of human B-cell development. We used human fetal bone marrow as a tissue source for BMSC and HSC, and the cells were supported in an exogenous serum/cytokine-free environment. This distinguishes our study from prior studies that used murine BMSC maintained in fetal bovine serum (5-7), or exogenous cytokine cocktails in a fetal bovine serum/horse serum-based culture (8) (Fig. 4) is a defining feature of our culture system. Prior studies (5-8) did not achieve this degree of B-cell differentiation, and in the study by Rawlings et al. (7) the predominant CD19+ population present after 3 months in culture had germ-line H chain genes.
Our results imply that the BMSC fibroblast-like cells provide the contact-dependent interactions and/or soluble mediators essential to support commitment and differentiation of HSC into the B lineage. The identity of the BMSC molecules critical for this process are unknown, but IL-6, IL-7, and SCF play little or no role. Neutralizing antibody against these three molecules had no effect on the tempo or phenotype of developing B cells. Formal exclusion of a role for these cytokines would require the use of human BMSC that fail to express of the respective genes or proteins.
The role of IL-7 in human B-cell development deserves special comment. IL-7 was not required for B-cell development in our BMSC culture, since in every experiment CD19+ cells emerged and expanded in the absence of exogenous IL-7 ( Table 1) . The results in Table 1 show enhancement of CD19+ B-lineage cell growth in cultures supplemented with in some experiments, but this result was neither consistently obtained or statistically significant. Importantly, even though BMSC in our culture system secrete small amounts of IL-7, neutralizing anti-IL-7 had no effect on the development or expansion of CD19+ B-lineage cells. IL-7 nonresponsive human B-cell progenitors were also described in a prior report (7) . We cannot dismiss the evidence supporting some role for in human B-cell development. Pro-B cells respond to IL-7 signaling by (i) modestly enhanced growth on BMSC (10), (ii) specific enhancement of cell surface CD19 (17, 18) , and (iii) downregulation of TdT, RAG-1, and RAG-2 (18) . In situ IL-7 expression at the mRNA level has also been detected in human bone marrow (19) .
Our results are consistent with the apparent IL-7-independent development of human B cells in vivo. Patients with X-linked severe combined immunodeficiency (XSCID) have mutations in the yc subunit (20, 21) that severely disrupt signaling through the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15. T-cell development is severely impaired in XSCID, but B-cell numbers are normal or elevated (22) . Since Yc is an essential signaling subunit of the IL-7R (23, 24) , one concludes that B-cell precursors in XSCID patients fail to respond to IL-7 (although to our knowledge this has not been formally demonstrated using B-cell precursors from XSCID patients). Further evidence for a negligible role of IL-7R/y, signaling in human B-cell development is the recent description of an autosomal severe combined immunodeficiency with mutations in the Janus family tyrosine kinase, Jak-3 (25, 26) . Patients with Jak-3 mutations have immunological characteristics similar to XSCID, including normal numbers of circulating B cells (25, 26) . These results are consistent with the known physical association between Jak-3 and Yc (27, 28) . Therefore, our in vitro results and experiments of nature point to little or no role for in at least the normal numerical development of human B cells. This is in striking contrast to the absolute dependency of murine B-cell development on IL-7/IL-7 receptor interactions (29) (30) (31) (32) , and subsequent downstream signaling involving Yc (33, 34) and Jak-3 (35, 36 
